Fundraising Fox

Centrexion Therapeutics

Baltimore, US · Founded 2013 · 4 known investors

centrexion.com ↗

Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development. The company operates in the biotechnology and pharmaceutical industry.

BiotechHealthtech

Founders & leadership

Centrexion Therapeutics was founded in 2013 by James N. Campbell.

JNJames N. Campbell
James N. CampbellPresident, Chief Scientific Officer
KL
Kerrie L. BradyExecutive
GB
Gregg BeloffExecutive
JBJeffrey B. Kindler
Jeffrey B. KindlerinChief Executive Officer
COCharles Oh
Charles OhChief Medical Officer
SSSmital Shah
Smital ShahActing CBO
MWMike Ward
Mike WardChief Financial Officer/Chief Operations Officer
JGJonathan Guerriero
Jonathan GuerrieroChief Development Operations Officer

Board

SZ
Shengda ZanBoard director
AL
Arnold L. OronskyBoard director
IB
Isaac BlechBoard director
SBSol Barer
Sol BarerBoard director

Investors · 4

Catalio Capital Management, LPNew York
EFung CapitalShenzhen
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Quan CapitalShanghai

Reported raises · per SEC filings

Form D private placements

$178.5M disclosed across 11 rounds · 2016–2023

▶$3.3MraisedJan 2024 · 116 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shawn TomaselloDirector
  • Michael J. WardExecutive Officer
  • James N. Campbell, M.D.Executive Officer, Director
  • Sol Barer, Ph.D.Director
  • Colin HillDirector
  • Randall M. StevensExecutive Officer
  • Joseph R. SwedishDirector
  • Jeffrey B. KindlerExecutive Officer, Director
  • J.C. Lopez, M.D.Director
Offering amount
$12.9M
Amount sold
$3.3M
Sales commissions
$1.3M
Placement agents
Maxim Group LLC
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael J. WardExecutive Officer
  • Shawn TomaselloDirector
  • Sol Barer, Ph.D.Director
  • Colin HillDirector
  • J.C. Lopez, M.D.Director
  • Jeffrey B. KindlerExecutive Officer, Director
  • Joseph R. SwedishDirector
  • Randall M. StevensExecutive Officer
  • James N. Campbell, M.D.Executive Officer, Director
Offering amount
$2.3M
Amount sold
$2.3M
Sales commissions
$230K
Placement agents
FCC Ltd., Maxim Group LLC
First sale
Nov 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.3MraisedJul 2023 · 124 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph R. SwedishDirector
  • Randall M. StevensExecutive Officer
  • Sol Barer, Ph.D.Director
  • Jeffrey B. KindlerExecutive Officer, Director
  • Colin HillDirector
  • Michael J. WardExecutive Officer
  • J.C. Lopez, M.D.Director
  • James N. Campbell, M.D.Executive Officer, Director
  • Shawn TomaselloDirector
Offering amount
$30M
Amount sold
$10.3M
Sales commissions
$3M
Placement agents
Maxim Group LLC
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$29.1MraisedAug 2022 · 47 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • J. C. Lopez, M.D.Director
  • Sol BarerDirector
  • Michael J. WardExecutive Officer
  • James N. Campbell, M.D.Executive Officer, Director
  • Peter WirthDirector
  • Shawn TomaselloDirector
  • Randall M. StevensExecutive Officer
  • Joseph R. SwedishDirector
  • Jeffrey B. KindlerExecutive Officer, Director
  • Colin HillDirector
  • Dezhi Kang, Ph.D.Director
Offering amount
$29.1M
Amount sold
$29.1M
Finders' fees
$2.6M
Placement agents
Maxim Group LLC
First sale
May 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.5MraisedJan 2021 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel MendelsonDirector
  • Sara NayeemDirector
  • Joseph R. SwedishDirector
  • Shawn TomaselloDirector
  • Stella XuDirector
  • James N. CampbellExecutive Officer, Director
  • Jeffrey B. KindlerExecutive Officer, Director
  • Sol BarerDirector
  • Randall M. StevensExecutive Officer
  • Michael J. WardExecutive Officer
Offering amount
$13.5M
Amount sold
$13.5M
Finders' fees
$945K
Placement agents
Maxim Group LLC
First sale
Jan 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$69.6MraisedJan 2018 · 67 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregg BeloffExecutive Officer
  • Sol J. BarerDirector
  • James N. CampbellExecutive Officer, Director
  • Arnold OronskyDirector
  • Sara NayeemDirector
  • Jeffrey B. KindlerExecutive Officer, Director
  • Isaac BlechDirector
  • Randall M. StevensExecutive Officer
  • Shawn TomaselloDirector
Offering amount
$69.6M
Amount sold
$69.6M
Sales commissions
$3.6M
Placement agents
Maxim Group LLC, Leerink Partners LLC
First sale
Dec 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.3MraisedMay 2017 · 40 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James N. CampbellExecutive Officer, Director
  • Sol J. BarerDirector
  • Jeffrey B. KindlerExecutive Officer, Director
  • Arnold OronskyDirector
  • Randall M. StevensExecutive Officer
Amount sold
$5.3M
Sales commissions
$212.4K
Placement agents
CIM Securities, LLC
First sale
Apr 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.6MraisedJan 2017 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kerrie L. BradyExecutive Officer
  • Sol BarerDirector
  • Shengda ZanDirector
  • Isaac BlechDirector
  • James N. CampbellExecutive Officer, Director
  • Jeffrey B. KindlerExecutive Officer
  • Arnold L. OronskyDirector
  • Gregg BeloffExecutive Officer
Offering amount
$16.6M
Amount sold
$16.6M
Minimum investment
$25K
Sales commissions
$1.3M
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Crew328 shared keywordsCrew32 maintains a database of compensation and workplace culture information that companies can compare against industry benchmarks. Its data is segmented by factors such as gender, experience level, region and company size, and includes startup salary figures indexed to the amount of venture funding a company has raised.

Companies competing with Centrexion Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Centrexion Therapeutics do?
Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development. The company operates in the biotechnology and pharmaceutical industry.
Who founded Centrexion Therapeutics?
Centrexion Therapeutics was founded by James N. Campbell in 2013.
Who are Centrexion Therapeutics's investors?
Centrexion Therapeutics's investors include Catalio Capital Management, LP, EFung Capital, New Enterprise Associates (NEA), Quan Capital.
How much funding has Centrexion Therapeutics raised?
Centrexion Therapeutics has disclosed $178.5M raised across 11 rounds.
Where is Centrexion Therapeutics headquartered?
Centrexion Therapeutics is headquartered in Baltimore, US.